Cutaneous Lesions in the Rat Following Administration of an Irreversible Inhibitor of erbB Receptors, Including the Epidermal Growth Factor Receptor

Toxicologic Pathology

Volumn 36, Issue 3, 2008, Pages 410-419

  Brown, Alan P ^a   Dunstan, Robert W ^a   Courtney, Cynthia L ^a   Criswell, Kay A ^a   Graziano, Michael J ^a  

^a PFIZER INC   (United States)

Author keywords

anticancer; canertinib; dermal toxicity; EGF receptor; oncology

Indexed keywords

CANERTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; MORPHOLINE DERIVATIVE; PROTEIN TYROSINE KINASE;

ALOPECIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CELL COUNT; CONTROLLED STUDY; DERMATITIS; DISEASE ASSOCIATION; DOSE RESPONSE; EPIDERMIS HYPERPLASIA; FEMALE; FOLLICULITIS; GASTROINTESTINAL TRACT; HAIR FOLLICLE; LEUKOCYTOSIS; MALE; NONHUMAN; PAPULAR RASH; PRIORITY JOURNAL; RAT; SKIN DEFECT; TOXICOKINETICS; VAGINA ATROPHY; ANIMAL; AREA UNDER THE CURVE; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG EFFECT; ERYTHEMATOSQUAMOUS SKIN DISEASE; LONGEVITY; ORAL DRUG ADMINISTRATION; PATHOLOGY; SKIN; TOXICITY TESTING; WISTAR RAT;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

ADMINISTRATION, ORAL; ALOPECIA; ANIMALS; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLICULITIS; LONGEVITY; MALE; MORPHOLINES; RATS; RATS, WISTAR; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SKIN; SKIN DISEASES, PAPULOSQUAMOUS; TOXICITY TESTS;

EID: 48549088945     PISSN: 01926233     EISSN: None     Source Type: Journal    
DOI: 10.1177/0192623308315827     Document Type: Article

References (43)

1. Adjei AA Signal transduction pathway targets for anticancer drug discovery Curr Pharm Design 2000 6 361 78
2. Albanell J Rojo F Averbach S Feyereislova A Mascaro JM Herbst R LoRusso P Rischin D Sauleda S Gee J Nicholson RI Baselga J Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition J Clin Oncol 2002 20 1 110 24
3. Allen LF Eiseman IA Fry DW Lenehan PF CI-1033, an irreversible panerbB receptor inhibitor and its potential application for the treatment of breast cancer Sem Oncol 2003 30 5, Suppl 16 65 78
4. Breedis C Regeneration of hair follicles and sebaceous glands from epithelium of scars in the rabbit Cancer Res 1954 14 575 79
5. Breider MA Irreversible inhibition of ERBB receptor family in rats results in epithelial atrophy and ulcerative dermatitis Proc Am Assoc Cancer Res 2000 41 493 (abstract 3142)
6. Brown AP Walsh KM Criswell KA Graziano M Toxicity of an irreversible Erb-B tyrosine kinase receptor inhibitor in rats Proc Am Assoc Cancer Res 2002 43 786 (abstract 3896)
7. Busam KJ Capodieci P Motzer R Kiehn T Phelan D Halpern AC Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225 Br J Dermatol 2001 144 1169 76
8. Campos SM Seiden MV Oza A Plante M Potkul R Hamid O Lenehan P Kaldjian E Jordan C Hirte H A phase 2, single agent study of CI-1033 administered at two doses in ovarian cancer patients who failed platinum therapy J Clin Oncol, 2004 ASCO Ann Meeting Proc (post-meeting edition) 2004 22 14S Abstract 5054
9. Cullen JM Ruebner BH Meeks RG Harrison SD Bull RJ A histopathologic classification of chemical-induced injury of the liver Hepatotoxicology 1991 Boca Raton, FL CRC Press 67 91
10. Dvir A Milner Y Chomsky O Gilon C Gazit A Levitzki A The inhibition of EGF-dependent proliferation of keratinocytes by tyrphostin tyrosine kinase blockers J Cell Biol 1991 113 4 857 65
11. Farrell GC Farrell GD Drug-induced cholestasis Drug-Induced Liver Disease 1994 New York Churchill Livingston 320 321
12. Gibbs JB Anticancer drug targets: growth factors and growth factor signaling J Clin Invest 2000 105 1 9 13
13. Goldenberg MM Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer Clin Therap 1999 21 2 309 18
14. Greaves P Histopathology of Preclinical Toxicity Studies: Interpretation and Relevance in Drug Safety Evaluation 2000 Amsterdam Elsevier
15. Hamid O Emerging treatments in oncology: focus on tyrosine kinase (erbB) receptor inhibitors J Am Pharm Assoc 2004 44 1 52 8
16. Hansen LA Alexander N Hogan ME Sundberg JP Dlugosz A Threadgill DW Magnuson T Yuspa SH Genetically null mice reveal a central role for epidermal growth factor receptor in the differentiation of the hair follicle and normal hair development Am J Pathol 1997 150 1959 75
17. Hidalgo M Siu LL Nemunaitis J Rizzo J Hammond LA Takimoto C Eckhardt SG Tolcher A Britten CD Denis L Ferrante K Von Hoff DD Silberman S Rowinsky EK Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies J Clin Oncol 2001 19 13 3267 79
18. Ito M Yang Z Andl T Cui C Kim N Millar SE Cotsarelis G Wnt-dependent de novo hair follicle regeneration in adult mouse skin after wounding Nature 2007 447 316 20
19. Johnson JR Cohen M Sridhara R Chen YF Williams GM Duan J Gobburu J Booth B Benson K Leighton J Hsieh LS Chidambaram N Zimmerman P Pazdur R Approval summary for Erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen Clin Cancer Res 2005 11 18 6414 21
20. Jost M Huggett TM Kari C Boise LH Rodeck U Epidermal growth factor receptor-dependent control of keratinocyte survival and Bcl-xL expression through a MEK-dependent pathway J Biol Chem 2001 276 9 6320 6
21. Kimyai-Asadi A Jih MH Follicular toxic effects of chimeric anti-epidermal growth factor receptor antibody cetuximab used to treat human solid tumors Arch Dermatol 2002 138 129 30
22. Lo Celso C Prowse DM Watt FM Transient activation of β-catenin signalling in adult mouse epidermis is sufficient to induce new hair follicles but continuous activation is required to maintain hair follicle tumours Development 2004 131 1787 99
23. Marti U Burwen SJ Jones AL Biological effects of epidermal growth factor, with emphasis on the gastrointestinal tract and liver: an update Hepatol 1989 9 1 126 38
24. Murillas R Larcher F Conti CJ Santos M Ullrich A Jorcano JL Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure EMBO J 1995 14 21 5216 23
25. National Research Council Guide for the Care and Use of Laboratory Animals 1996 Washington, DC National Academy Press
26. Nemunaitis J Eiseman I Cunningham C Senzer N Williams A Lenehan PF Olson SC Bycott P Schlicht M Zentgraff R Shin DM Zinner RG Phase I clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory cancer Clin Cancer Res 2005 11 10 3846 53
27. Perez-Soler R Saltz L Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining ? J Clin Oncol 2005 23 22 5235 46
28. Peus D Hamacher L Pittelkow MR EGF-receptor tyrosine kinase inhibition induces keratinocyte growth arrest and terminal differentiation J Invest Dermatol 1997 109 751 6
29. Philpott MP Kealey T Effects of EGF on the morphology and patterns of DNA synthesis in isolated human hair follicles J Invest Dermatol 1994 102 186 91
30. Powell TJ Ben-Bassat H Klein BY Chen H Shenoy N McCollough J Narog B Gazit A Harzstark Z Chaouat M Levitzki R Tang C McMahon J Shawver L Levitzki A Growth inhibition of psoriatic keratinocytes by quinazoline tyrosine kinase inhibitors Br J Dermatol 1999 141 802 10
31. Raymond E Faivre S Armand JP Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy Drugs 2000 60 Suppl 1 15 23
32. Rinehart JJ Wilding G Willson J Krishnamurthi S Natale R Mani S Burnett D Olson S Bycott P Owens-Grillo JK Hes M Lenehan P A phase 1 clinical and pharmacokinetic study of oral CI-1033, a pan-erbB tyrosine kinase inhibitor, in patients with advanced solid tumors Proc Am Soc Clin Oncol 2002 21 Abstract 41
33. Robert C Soria JC Spatz A Le Cesne A Malka D Pautier P Wechsler J Lhomme C Escudier B Boige V Armand JP Le Chevalier T Cutaneous side-effects of kinase inhibitors and blocking antibodies Lancet Oncol 2005 6 491 500
34. Rowinsky EK Garrison M Lorusso P Patnaik A Hammond L De Bono J McCreery H Eiseman I Lenehan P Tolcher A Administration of CI-1033, an irreversible pan-erbB tyrosine kinase (TK) inhibitor is feasible on a 7-day-on/7-day-off schedule: a phase I, pharmacokinetic (PK), and food effect study Proc Am Soc Clin Oncol 2003 22 Abstract 807
35. Segaert S Van Cutsem E Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors Ann of Oncol 2005 16 1425 33
36. Shamoto M Osada A Shinzato M Kaneko C Yoshida A Do epidermal Langerhans’ cells, migrating from skin lesions, induce the paracortical hyperplasia of dermatopathic lymphadenopathy? Pathol Intl 1996 46 348 54
37. Slichenmyer WJ Elliott WL Fry DW CI-1033, a pan-erbB tyrosine kinase inhibitor Sem Oncol 2001 28 5, Suppl 16 80 5
38. Stoll SW Benedict M Mitra R Hiniker A Elder JT Nunez G EGF receptor signaling inhibits keratinocyte apoptosis: evidence for mediation by Bcl-XL Oncogene 1998 16 1493 9
39. Tarnawski AS Jones MK The role of epidermal growth factor (EGF) and its receptor in mucosal protection, adaptation to injury, and ulcer healing: involvement of EGF-R signal transduction pathways J Clin Gastroenterol 1998 27 Suppl 1 S12 20
40. Umeda-Ikawa A Ishii Y Suzuki K Uetsuka K Nakayama H Doi K Dorsal skin responses to topical application with hydrogen peroxide in mini and Wistar rats Exp Toxic Pathol 2002 54 239 44
41. Van Doorn R Kirtschig G Scheffer E Stoof TJ Giaccone G Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor Br J Dermatol 2002 147 598 601
42. Van Mater D Kolligs FT Dlugosz AA Fearon ER Transient activation of β-catenin signaling in cutaneous keratinocytes is sufficient to trigger the active growth phase of the hair cycle in mice Genes Dev 2003 17 1219 24
43. Zinner RG Nemunaitis J Eiseman I Shin HJC Olson SC Christensen J Huang X Lenehan PF Donato NJ Shin DM Phase I clinical and pharmacodynamic evaluation of oral CI-1033 in patients with refractory cancer Clin Cancer Res 2007 13 10 3006 14